[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@PDUFA_Pulse Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1688765842757238784.png) @PDUFA_Pulse PDUFA Pulse

PDUFA Pulse posts on X about $amgn, checkpoint, $kura, $beam the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1688765842757238784/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1688765842757238784/c:line/m:interactions.svg)

- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXX +849%
- X Year XXXXXX +72%

### Mentions: X [#](/creator/twitter::1688765842757238784/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1688765842757238784/c:line/m:posts_active.svg)

- X Week XX -XX%
- X Month XX -XXXX%
- X Months XX +963%
- X Year XX +571%

### Followers: XXX [#](/creator/twitter::1688765842757238784/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1688765842757238784/c:line/m:followers.svg)

- X Week XXX +4.70%
- X Month XXX +30%
- X Months XXX +156%
- X Year XXX +174%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1688765842757238784/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1688765842757238784/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  XXXXX% [cryptocurrencies](/list/cryptocurrencies)  XXXXX%

**Social topic influence**
[$amgn](/topic/$amgn) 5.88%, [checkpoint](/topic/checkpoint) 5.88%, [$kura](/topic/$kura) 5.88%, [$beam](/topic/$beam) 5.88%, [$mdgl](/topic/$mdgl) 5.88%, [$galt](/topic/$galt) 5.88%, [$akro](/topic/$akro) 5.88%, [$jnj](/topic/$jnj) 5.88%, [ash](/topic/ash) 5.88%, [$agio](/topic/$agio) XXXX%

**Top accounts mentioned or mentioned by**
[@runlolarn](/creator/undefined)

**Top assets mentioned**
[Amgen, Inc. (AMGN)](/topic/$amgn) [BEAM (BEAM)](/topic/$beam) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Akropolis (AKRO)](/topic/$akro) [Johnson & Johnson (JNJ)](/topic/$jnj) [Agios Pharmaceuticals, Inc. (AGIO)](/topic/$agio) [Muhdo Hub (DNA)](/topic/$dna)
### Top Social Posts
Top posts by engagements in the last XX hours

"📈 THE 6-MONTH REVOLUTION: Amgen & GSK aim to kill the daily pill.The second half of December isn't just about approval; it's about Lifestyle Leverage. 🧠 Dec 14: $AMGN (Amgen) Uplizna (gMG) The Edge: While competitors like Vyvgart require frequent infusions Uplizna brings a twice-yearly dosing schedule to Myasthenia Gravis. In a crowded neurology market convenience is the ultimate moat. 🫁 Dec 16: $GSK Depemokimab (Asthma & CRSwNP) The Edge: The First Ultra-Long-Acting Biologic.We are talking about switching from daily inhalers/pills to just two shots a year. Indication 1: Severe Asthma"  
[X Link](https://x.com/PDUFA_Pulse/status/1996282787339669565)  2025-12-03T18:18Z XXX followers, XXX engagements


"Big news from #SABCS25: BioNTech + Bristol Myers Squibb just dropped promising Phase X data for pumitamig a PD-L1 VEGF-A bispecific in pretreated triple-negative breast cancer.Key highlights: Encouraging ORR and PFS in a tough-to-treat population Potential first-in-class combo hitting both immune checkpoint and angiogenesis Another step forward for patients with TNBC who desperately need new options. #Oncology #Immunotherapy #BreastCancer Full data presented today in San Antonio"  
[X Link](https://x.com/PDUFA_Pulse/status/1998386826059620782)  2025-12-09T13:38Z XXX followers, XXX engagements


"🧬 Forget the Santa Rally its ASH Season. The American Society of Hematology (ASH) meeting kicks off this weekend (Dec 6-9) and the abstracts are already moving markets. While we watch the PDUFA calendar keep an eye on data readouts from $KURA (Kura Oncology) and $BEAM (Beam Therapeutics). The focus this year is heavily on Menin inhibitors and next-gen gene editing for Sickle Cell"  
[X Link](https://x.com/PDUFA_Pulse/status/1995930974325215702)  2025-12-02T19:00Z XXX followers, XXX engagements


"Nov XX - $MDGL Rezdiffra (resmetirom MASH) PoA XX % The NASH kingpin reports again. Phase X follow-ups for Rezdiffra. $XX B cap $XXX M cash burn. $GALT $AKRO"  
[X Link](https://x.com/PDUFA_Pulse/status/1987952375727091804)  2025-11-10T18:35Z XXX followers, XXX engagements


"Just in from ASH 2025: J&Js Tecvayli + Darzalex combo is showing a flattened OS curve in relapsed multiple myeloma. A potential functional cure signal in XX% of patients after X years. Biggest myeloma advance in decades. $JNJ"  
[X Link](https://x.com/PDUFA_Pulse/status/1998734757811859896)  2025-12-10T12:41Z XXX followers, XXX engagements


"PDUFA TODAY: Agios $AGIO Pyrukynd Label Expansion (/-thalassemia) The Analyst View: Agios is testing the regulatory ceiling for its hematology franchise. While approval probabilities are high (directional 70%) the real alpha lies in the label language. A narrow indicationor a label burdened with restrictive surveillancewill cap the commercial ramp. The Market Structure Risk: Entering the second liquid week of December we are in a "Repricing Vacuum." Institutional bids thin out daily. In this structure failure (CRL) triggers an air-pocket decline while success (Approval) often faces muted"  
[X Link](https://x.com/PDUFA_Pulse/status/1997697235052810671)  2025-12-07T15:58Z XXX followers, 1289 engagements


"Ginkgo Bioworks $DNA just secured a $47M contract from the U.S. Department of Energy to build the countrys first fully autonomous AI-powered microbial labs This is part of the Genesis Mission push to accelerate biofuels sustainable materials and next-gen therapeutics using robotics + AI. From years months for strain engineering Possibly a game-changing infrastructure move"  
[X Link](https://x.com/PDUFA_Pulse/status/1998515540390977880)  2025-12-09T22:10Z XXX followers, XXX engagements


"📰Roche just dropped blockbuster Phase X data for its oral SERD in early breast cancer: XX% lower risk of recurrence or death vs standard endocrine therapy. First big oral alternative to injectables in decades. $RHHBY $ROG.SW This ones going to move the needle in HR+ breast cancer treatment"  
[X Link](https://x.com/PDUFA_Pulse/status/1998858649830302127)  2025-12-10T20:53Z XXX followers, XXX engagements